Neringa Barmute

Industry Partnerships and Commercialisation Executive, Medicine

Neringa is a Technology Transfer professional with a focus on Medicine and Life Sciences. She has experience in both academic research commercialisation and industrial IP management, having worked for companies like Oxford BioMedica and Thermo Fisher Scientific. Neringa manages an extensive IP portfolio, mainly focussed on advanced therapies, infectious diseases and diagnostics. She is responsible for evaluating and protecting inventions, technology marketing, spinouts and license negotiations, also for training researchers about intellectual property.

Neringa's portfolio

MicroRNA Biomarkers for ectopic or intrauterine pregnancy

MicroRNA Biomarkers for ectopic or intrauterine pregnancy

MicroRNA are important gene regulators and their expression profiles change with pathophysiology, allowing their use as biomarkers. Imperial researchers have identified differential markers that can distinguish pregnancy of unknown location (PUL). Find out more

Zinc finger therapy for Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD)

Zinc finger therapy for Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD)

A zinc finger to target both the ALS and FTD therapeutically Find out more

Zinc finger therapy for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

Zinc finger therapy for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

A zinc finger (zf) to target the FXTAS mutation therapeutically Find out more

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs). Find out more

Methods to scale production of hPSC-derived endothelial cells

Methods to scale production of hPSC-derived endothelial cells

A new 3D-culture methodology using stirred-tank bioreactors as a scalable platform for the production of hPSC-derived endothelial cells Find out more

Human monoclonal antibodies to COVID-19

Human monoclonal antibodies to COVID-19

A suite of broad neutralising monoclonal antibodies (bnMABs) isolated to be used for treatment of coronaviruses with a focus on SARS-CoV-2 (2019-nCoV). Find out more

High-resolution transcription start site mapping using nanogram-levels of total RNA immunoprecipitation (SLIC-CAGE)

High-resolution transcription start site mapping using nanogram-levels of total RNA immunoprecipitation (SLIC-CAGE)

A novel development of the cap-trapper CAGE protocol which can generate complex high-quality libraries for as little as 5-10 nanograms of cellular RNA. Find out more

Management of pre-term labour via an application for pathway selective EP2 agonist

Management of pre-term labour via an application for pathway selective EP2 agonist

An EP2 receptor agonist with an application as a novel tocolytic for the management of pre-term labour. Find out more

MicroRNA plasma markers for small-for-gestational-age (SGA) births

MicroRNA plasma markers for small-for-gestational-age (SGA) births

Markers to determine the risk of SGA births based on miRNA plasma detected from maternal blood samples. Find out more

Circuit design for limiting Mycoplasma growth to bioreactors

Circuit design for limiting Mycoplasma growth to bioreactors

Novel genetic engineering tools that can be applied to Mycoplasma expanding its utility as a synthetic biology asset. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...